Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Osemitamab by Transcenta for Lung Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Lung Cancer. According to GlobalData, Phase II...
Osemitamab by Transcenta for Gastric Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Osemitamab by Transcenta for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Osemitamab by Transcenta for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Osemitamab by Transcenta for Gallbladder Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...
Osemitamab by Transcenta for Solid Tumor: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Osemitamab by Transcenta for Ovarian Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
Osemitamab by Transcenta for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
Osemitamab by Transcenta for Pancreatic Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...